Reconstitution & dose calculator
Ramp-up and maintenance — the most important section on this page
Phase 1: Ramp-up (weeks 1–4). NAD+ is the most dose-sensitive compound on this site. Going slow is non-negotiable; "I'll just start at the maintenance dose" is the most common way people end up with the chest pressure, anxiety, flushing, or GI symptoms that make NAD+ feel terrible. A typical ramp:
- Week 1: 50 mg/day — assess baseline tolerance
- Week 2: 100 mg/day if week 1 was clean
- Week 3: 150 mg/day if still clean
- Week 4: 200 mg/day — this is the working maintenance dose for most people
Phase 2: Maintenance (week 4 onward). Once you've ramped to a comfortable working dose, you have flexibility. Daily 100–200 mg works for many people. Others run the working dose 2–3 times per week instead, since NAD+ has a meaningful half-life and daily isn't strictly necessary once tissue levels are up. Some run 4 weeks on / 1 week off for a clearance window. None of these patterns is clearly superior — pick the one that fits your schedule and re-evaluate.
If side effects appear at any point: drop the dose by 50 mg, hold for a week at the lower dose, and re-attempt the higher dose only after symptoms have fully resolved. Don't push through. Side effects don't mean "it's working" — they mean the dose is moving faster than your body can handle. Slow injection rate (over 30–60 seconds rather than a quick push) also helps significantly.
Don't go above 250 mg per SubQ injection. Above this, volume becomes unwieldy, absorption gets less reliable, and the side-effect profile gets worse. If you need higher per-session doses, IV is the appropriate route — with appropriate clinical setup.
The honest read. Subjective reports of energy and clarity from NAD+ are real and consistent. Whether that effect is specifically NAD+ doing something durable for healthspan or aging, versus a near-term metabolic boost combined with placebo and routine, hasn't been rigorously disentangled. Don't extrapolate from "feels good" to "extends lifespan" — the human outcomes data isn't there.
For educational and research purposes only. This is not medical advice. NAD+ is not FDA-approved as a drug for any indication. Compounded forms operate outside FDA drug oversight. Long-term safety and outcomes data are limited. Consult a licensed healthcare provider before any health decision.